Entering text into the input field will update the search result below

Biotech Analysis Central Preview Series: BioLineRX

Jul. 17, 2020 12:40 PM ETBioLineRx Ltd. (BLRX)1 Comment
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Long Only, Biotech, Healthcare, Short Only

Seeking Alpha Analyst Since 2011

I am the Founder of Biotech Analysis Central, A subscription service on Seeking Alpha's Marketplace. If you want to learn more about biotech investing or you want to check out my biotech analysis you can do so with a free 2-week trial to my service. Just hit the "Learn More" button on the bottom of the Marketplace Research Tab. I have a Bachelors of Applied Science Degree In Technology Management, Industrial and Business Services Management from St. Petersburg College Florida. I have been investing in biotech stocks for many years, and I prefer to invest as a long term investor. With that In mind I seek stocks that have long term value! I primarily Like to Invest In biotechnology stocks and I accept the risks. I Write for the Healthcare Sector and Stock market in general. I contribute to Seeking Alpha.

You can follow me on stocktwits.com under the name BiopharmaPro where I currently have (62.5K) followers. Join me in my quest to find the best biotechnology stocks that deliver results to help patients with new treatment options.

This is a preview blog series on what you can expect when subscribing to my "Biotech Analysis Central" service marketplace. For the full article you must subscribe to my service. This is just an intro of two snippets on the research articles that are written. Thus far, there are about 100+ research reports on both both small-cap and mid-cap biotech stocks with full analysis of the pipeline, catalysts, financials, and clinical trial analysis. If you want to read more then please subscribe to my marketplace service. As always I offer a 2-week free trial just to show you how helpful my service is. You can cancel anytime before the 2-week free trial is up and never be charged a dime.

First Section Of Marketplace Article (This article piece was originally written on July 9, 2020)

The next article I wanted to discuss for the "Biotech Analysis Central Stock Insight Series" is a biotech by the name of BioLineRx (BLRX). The reason why I wanted to go over this biotech next is because it has an upcoming catalyst in mid-2020 any day now. This involves results from a phase 2 using BL-8040 in combination with Keytruda plus chemotherapy to treat heavily pre-treated pancreatic cancer patients. Preliminary data was already released back in December of 2019 and then again a few months ago in May of 2020. What was not revealed was overall survival (OS) and Progression-free survival (PFS) for the triple-combination regimen. This is the data due any day now and if positive, could create a huge spike for the stock price. The risk is that pancreatic cancer is tough to treat, therefore, I view this near-term data as being risky. The good news is that BL-8040 (MOTIXAFORTIDE) had already achieved positive results in a phase 2 study treating multiple myeloma (MM) patients that go through stem-cell treatment. This program is already in a phase 3 study and it is believed that good data could come from this study, in terms of meeting the primary endpoint. The results from this phase 3 study are due by the end of 2020. Then, there is another catalyst also expected towards the end of this year. This involves a phase 2b study using BL-8040 along with high-dose cytarabine to treat patients with acute myeloid leukemia (AML). Some positive preliminary data was shown for each of these indications, but there is no guarantee that long-term treatment improved the data. Still, BioLineRx is trading at $1.77 per share. In the worst case scenario if the upcoming pancreatic cancer study doesn't succeed, the stock would trade lower by 50% to roughly .70 or .80 cents per share. From there, it may become a more attractive buy towards the phase 3 trial results expected at the end of 2020.

Conclusion Of Marketplace Article

The Final Verdict is that BioLineRX is a decent speculative biotech. I am airing on the side of caution primarily because the data readout in pancreatic cancer to be readout any day now in mid-2020 is risky. This is a large market opportunity with an unmet need and positive data would be a game changer. The global pancreatic cancer market is expected to exceed $13 billion by 2023. Preliminary data was not that bad, but this population is hard to treat. Where an investor may recover is later on once the phase 3 GENESIS study is readout. Helping these transplant patients with MM will be a good thing. The global multiple myeloma market is expected to reach $27.8 billion by 2027. Even if you only account for a portion of the market that goes through an Autologous transplant for MM, it will still be a good market opportunity in terms of revenue. As long as the primary endpoint is hit, then this program will be in good shape. The good news is that BL-8040 has multiple indications it is being developed for. Hypothetically even if this drug doesn't work out, BioLineRx has been able to acquire AGI-134. This drug's ability to target the large solid tumor market is quite crucial. I don't believe that BL-8040 will suffer a bad fate. It has several shots on goal in stem-cell mobilization (transplant MM patients), AML and pancreatic cancer. There even is an advancement of this drug in early-stage testing to treat patients with gastric cancer. The AML and solid tumor markets themselves are also multi-billion dollar markets. These are other shots on goal with massive potential. I believe BioLineRX is a good speculative biotech based on preliminary findings to date. As long as BL-8040 can be proven in one late-stage study, then it will be golden as a biotech for a long period of time.

Analyst's Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.